Trial Design
The primary objective of the PEGASUS-TIMI 54 trail was...
a. to compare the efficacy of ticagrelor with clopidogrel in acute coronary syndrome patients
b. to evaluate the long-term use of ticagrelor in post-MI patients for secondary prevention of CV events
c. to evaluate the long-term use of clopidogrel in post-MI patients for secondary prevention of CV events
d. to determine the impact of ticagrelor on reducing afib recurrence
What is B
b. to evaluate the long-term use of ticagrelor in post-MI patients for secondary prevention of CV events
The primary efficacy end point was...
a. Composite of cardiovascular death, MI, and hypoglycemic events
b. Composite of cardiovascular death, MI, or stroke
c. Cardiovascular death and death from any cause
d. All cause mortality
What is B
b. Composite of cardiovascular death, MI, or stroke
Based on PEGASUS-TIMI-54, the major consideration before taking ticagrelor is...
a. Patient’s kidney function
b. Patients cholesterol levels
c. Patients bleeding risk
d. Patients blood sugar
What is C
c. Patients bleeding risk
The study design was...
a. 1:1 random assignment, placebo controlled, double-blind blinded
b. 1:1 random assignment, placebo controlled, only patients blinded
c. 1:1:1 random assignment, placebo controlled, only patients blinded
d. 1:1:1 random assignment, placebo controlled, double-blind blinded
What is D
d. 1:1:1 random assignment, placebo controlled, double-blinded
The primary safety end point was...
a. TIMI major bleeding
b. Intracranial hemorrhage
c. Fatal bleeding
d. Hypoglycemic event
What is A
a. TIMI major bleeding
TIMI stands for...
a. Thrombolysis In Myocardial Infarction
b. Thrombocytopenia in Myocardial Infarction
c. Thrombolysis in My Inner-ear
d. Thrombocytosis in Myocardial Infarction
What is A
a. Thrombolysis In Myocardial Infarction
The treatment groups in the PEGASUS-TIMI 54 trial was...
a. Ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, and placebo
b. Ticagrelor 90 mg once daily, ticagrelor 60 mg once daily, and aspirin alone
c. Ticagrelor 90 mg twice daily, prasugrel 10 mg once daily, and placebo
d. Ticagrelor 60 mg twice daily, clopidogrel 75 mg once daily, and placebo
What is A
a. Ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, and placebo
The cause of the majority of premature discontinuation in the patients randomized to the ticagrelor group was...
a. nonadherence
b. Development of diabetes
c. Adverse events including bleeding events
d. None of the above
What is C
c. Adverse events including bleeding events
All of the following patients do not fit the inclusion criteria except...
a. A 46-year-old male with a history of MI 1.5 years ago
b. A 62-year-old female with an MI 4 months ago, currently on cilostazol therapy
c. A 58-year-old female with an MI 2 years ago and a CrCl of 42 mL/min
d. A 52-year-old male with an MI 4 years ago, currently receiving guideline-directed therapy for T2DM
What is C
c. A 58-year-old female with an MI 2 years ago and a CrCl of 42 mL/min
T primary efficacy analysis conducted in a ___ manner
a. Noninferiority
b. Intention to treat
c. Hierarchical (with the inclusion of secondary endpoints)
What is B
b. Intention to treat
Those included in the safety analyses were...
a. Patients who underwent randomization and received treatment for at least 3 months
b. Patients who underwent randomization and received treatment for at least 6 months
c. Patients who underwent randomization and did not discontinue treatment early
d. All patients who underwent randomization and received at least one dose of the study drug
What is D
d. All patients who underwent randomization and received at least one dose of the study drug
True or False: The trial demonstrated that ticagrelor 90 mg BID was the preferred long-term dose for secondary prevention.
what is a false statement